Adding everolimus to exemestane improved PFS in postmenopausal women with HR+ advanced breast cancer, according to results of a phase 3 trial reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Adding bevacizumab to first-line chemotherapy and trastuzumab was safe and well tolerated in patients with HER2+ metastatic breast cancer; however, no significant differences in clinical benefit or measurements in circulating tumor cells (CTCs) were observed, according to results of a phase 3 clinical trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Topotecan plus carboplatin failed to improve progression-free survival (PFS) or overall survival (OS) compared with standard therapy (paclitaxel/carboplatin, gemcitabine/carboplatin, or carboplatin/pegylated doxorubicin) in patients with platinum-sensitive relapsed ovarian cancer, according to results of the randomized phase 3 HECTOR study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Please login or register first to view this content.
